Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to “Hold” Rating

Personalis (NASDAQ:PSNL) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Other equities research analysts have also issued research reports about the stock. Guggenheim increased their price objective on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. HC Wainwright lifted their price objective on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. BTIG Research lifted their price objective on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of Personalis in a research report on Wednesday, November 5th. Finally, Morgan Stanley raised their target price on Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a report on Monday, December 1st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Personalis has an average rating of “Moderate Buy” and an average target price of $10.57.

Personalis Stock Performance

PSNL stock opened at $8.77 on Friday. The firm has a market cap of $778.78 million, a P/E ratio of -9.97 and a beta of 1.99. The stock’s 50 day moving average price is $9.02 and its 200 day moving average price is $6.90. Personalis has a 1 year low of $2.83 and a 1 year high of $11.40.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. On average, research analysts predict that Personalis will post -1.4 earnings per share for the current year.

Insider Activity

In related news, CEO Christopher M. Hall sold 29,612 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in PSNL. Aberdeen Group plc boosted its stake in shares of Personalis by 472.3% during the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after purchasing an additional 1,406,895 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Personalis by 33.9% in the first quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after purchasing an additional 17,056 shares during the last quarter. EntryPoint Capital LLC lifted its stake in shares of Personalis by 76.0% in the 1st quarter. EntryPoint Capital LLC now owns 83,628 shares of the company’s stock valued at $294,000 after purchasing an additional 36,115 shares during the last quarter. Trexquant Investment LP lifted its stake in Personalis by 455.0% during the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock worth $432,000 after purchasing an additional 100,804 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.